Plain-English translation of NCT06466850 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing mesenchymal stem cell derived exosomes — tiny healing particles that carry anti-inflammatory molecules — as a treatment for knee osteoarthritis. Researchers believe these particles may help reduce the inflammation and joint damage that causes arthritis pain and swelling. The study will evaluate whether this treatment can help people with moderate osteoarthritis feel better and move more easily.
Standard osteoarthritis treatments like pain medication and injections don't work for everyone, and many don't stop the underlying joint damage from getting worse. This trial exists because early research suggests this treatment might actually help reduce inflammation and protect the joint in new ways that current therapies cannot.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive an injection of the treatment particles into your affected knee. The trial will track your symptoms, pain levels, and how well your knee functions over time. You'll likely have follow-up visits to monitor how you're responding and whether the treatment is helping reduce your pain and swelling.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Iran
Enrollment target
~20 participants
Started
January 2024
Primary completion
December 2026
Age range
45 Years – 75 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Leila Dehghani, Dr
Isfahan University of Medical Sciences
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.